Cascade Catalysis Towards Synthesis of Phorbol Architecture

佛波醇结构合成的级联催化

基本信息

  • 批准号:
    7420931
  • 负责人:
  • 金额:
    $ 4.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-05-01 至 2009-10-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): While nature's production of molecular agents, especially those with biological activity, are achieved in a relatively short number of chemical transformations, synthetic chemists' approaches to molecules are not as streamlined and thus neither as efficient nor effective. Emulation of nature's biosynthetic processes will provide valuable lessons for advancing the capability of chemists to access molecular structures of importance. The development of a biomimetic process, where sequential catalytic manipulations are achieved through utilization of multiple catalysts without isolation of intermediates, should enhance the chemist's ability to approach architectures of biologically active molecules in a more effective fashion. In this proposal, the applicability of cascade catalysis will be tested in the context of the phorbol architecture, specifically in the total synthesis of 12-deoxy phorbol. Phorbol, a potent tumor promoter, has been one of the most important natural products that has been used in studies to decipher the mechanism of the carcinogenesis. More recently, its derivatives have demonstrated anti-tumor, analgesic, and anti-HIV activities. Due to these significant biological implications, access to phorbol and its congeners have become very important. "The proposed synthesis will take advantage of cascade catalysis to access the desired molecular architecture in a short, efficient, and deliberate manner with control of enantio- and diastereoselectivity. The modular nature of the synthesis will allow the devised strategy to be applicable towards a wide range of the molecular structures within the phorbol family. Relevance to public health: 12-deoxy phorbol ester derivatives have demonstrated potential as anti-tumor agents. Studies of efficient synthetic access to the parent structure, 12-deoxy phorbol, will prove beneficial towards development of anti-tumor medicines.
描述(由申请人提供):虽然自然界分子制剂的生产,特别是那些具有生物活性的,是在相对较少的化学转化中实现的,但合成化学家对分子的方法并不那么精简,因此既不高效也不有效。模拟自然界的生物合成过程将为提高化学家获得重要分子结构的能力提供宝贵的经验教训。仿生过程的发展,通过使用多种催化剂而不分离中间体来实现顺序催化操作,应该提高化学家以更有效的方式接近生物活性分子结构的能力。在本提案中,级联催化的适用性将在基团结构的背景下进行测试,特别是在12-脱氧基团的全合成中。佛波是一种强效的肿瘤促进剂,是研究肿瘤发生机制最重要的天然产物之一。最近,其衍生物已被证明具有抗肿瘤、镇痛和抗艾滋病毒活性。由于这些重要的生物学意义,获得象素及其同系物变得非常重要。“拟议的合成将利用级联催化以短、高效和慎重的方式获得所需的分子结构,并控制对映体和非对映体选择性。合成的模块化性质将允许设计的策略适用于广泛的phobol家族内的分子结构。与公共卫生相关:12-脱氧磷酯衍生物已被证明具有抗肿瘤药物的潜力。对母体结构12-脱氧佛波的高效合成途径的研究,将有助于抗肿瘤药物的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HAHN KIM其他文献

HAHN KIM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HAHN KIM', 18)}}的其他基金

Cascade Catalysis Towards Synthesis of Phorbol Architecture
佛波醇结构合成的级联催化
  • 批准号:
    7274587
  • 财政年份:
    2007
  • 资助金额:
    $ 4.68万
  • 项目类别:
Cascade Catalysis Towards Synthesis of Phorbol Architecture
佛波醇结构合成的级联催化
  • 批准号:
    7612096
  • 财政年份:
    2007
  • 资助金额:
    $ 4.68万
  • 项目类别:

相似海外基金

Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
  • 批准号:
    10641500
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
  • 批准号:
    10485593
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
  • 批准号:
    10728526
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
  • 批准号:
    10638278
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
  • 批准号:
    10621646
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10425794
  • 财政年份:
    2022
  • 资助金额:
    $ 4.68万
  • 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
  • 批准号:
    22K19602
  • 财政年份:
    2022
  • 资助金额:
    $ 4.68万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
  • 批准号:
    10512672
  • 财政年份:
    2022
  • 资助金额:
    $ 4.68万
  • 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10721752
  • 财政年份:
    2022
  • 资助金额:
    $ 4.68万
  • 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
  • 批准号:
    10821681
  • 财政年份:
    2022
  • 资助金额:
    $ 4.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了